# Wall Street's Wildest Stock Showdowns: Bulls vs. Bears!

Newsy: Bud Fox's 3 Controversial Stocks of the Day
Published: 2026-10-01T01:33:00.664Z
Source: https://newsyai.com/edition/c62a4a16-3be6-46fb-a1b1-fc491be3eaec
Archive: https://newsyai.com/newsy/bde0e0f6-7fac-4abb-93a8-996b5464e3e9.md

---

**Wall Street's Most Polarizing Shitshows: 3 Stocks Where Bulls and Bears Are Throwing Hands (and Maybe Some Feces) — Fresh Edition, October 1, 2026**[[1]](https://www.findmymoat.com/short-interest)[[2]](https://thedesperatetrader.com/most-shorted-stocks)

Futures mixed—Dow flat, Nasdaq mainlining the AI hype like it's the fountain of youth, crude oil bouncing like a caffeinated squirrel on a trampoline. Last round's fast-food flops, 3D printer dreams, and fuel-cell fantasies? Yesterday's news. These three tickers have the Street more divided than a crypto bro at a family reunion. Elevated short interest across the board (flirting with 30-50%+ of float and days-to-cover that screams volatility potential), fresh short data, filings, and chatter only—no reruns. Bulls see structural tailwinds and squeeze fuel; bears see valuation traps, execution flops, dilution landmines, competition overhangs, and fading relevance. Then the first-principles hammer drops.[[3]](https://shortinteresttracker.com/most-shorted-stocks)

### 1. Ondas Holdings (ONDS) – Drone/Rail Tech Savior or Serial Cash Incinerator in a Commoditized Connectivity Graveyard?
ONDS features elevated short interest (~40-61% of float in recent trackers, with days-to-cover around 3-4), with the market split on an industrial automation and drone play for rail and critical infrastructure.[[1]](https://www.findmymoat.com/short-interest)[[3]](https://shortinteresttracker.com/most-shorted-stocks)

**Bull Case (The "AI/Drone Tailwinds, Rail Contracts, and Infrastructure Boom Crew")**  
Bulls highlight surging demand for autonomous systems in rail and energy sectors, new product launches expanding addressable markets, potential large-scale deployments, and analyst optimism for long-term infrastructure role. Short interest hints at squeeze upside on order wins or sector rallies. Some see it as a high-conviction play on industrial digitization and AI-enabled connectivity.

**Bear Case (The "Backlog Conversion Risks, Manufacturing Scale Challenges, Cash Burn/Dilution Risks, and 'Will It Ever Scale Profitably?' Crew")**  
Bears cite ongoing questions around converting proposals to firm revenue, production ramp hurdles, persistent negative cash flows requiring potential dilutive raises, intense competition, and historical precedent of hardware/tech plays struggling with profitability. Short buildup reflects skepticism that the vision justifies the price amid macro and execution hurdles.[[4]](https://www.marketbeat.com/articles/is-the-market-right-or-wrong-about-these-4-high-short-interest-stocks/)

**My First-Principles Take**: Industrial tech value accrues to players with defensible tech/IP, scalable manufacturing, diversified end-markets, and paths to positive unit economics/margins—economics reward capital discipline and market adaptation over pure R&D bets in a competition-, technology adoption-, capex-, and cycle-sensitive field. ONDS has genuine tailwinds from targeted growth areas and product momentum, but durable profits only come if cash burn moderates without endless dilution, differentiation holds vs. rivals, and revenue scales meaningfully. The drone/rail bet is directionally exposed to industrial innovation trends, yet it's an execution-, capital-, and macro-sensitive play prone to volatility and multiple compression. At these short levels, volatility rocket fuel—catalysts roast bears; stumbles feed the fire.

### 2. Recursion Pharmaceuticals (RXRX) – AI Drug Discovery Pioneer or Serial Diluter in a Biotech Graveyard?
RXRX sports elevated short interest (~33-35% of float in recent data, with days-to-cover around 12-13+), fueled by debate on AI-powered drug discovery.[[1]](https://www.findmymoat.com/short-interest)[[5]](https://www.strasmore.com/blog/most-shorted-stocks)

**Bull Case (The "AI Platform Advantages, Pipeline Momentum, and Pharma Partnerships Crew")**  
Bulls point to growth in prioritized AI-driven discovery segments, new platforms and partnerships expanding addressable markets, cost structure adjustments preserving R&D, and potential for clinical validation to unlock re-rating. Short interest hints at squeeze upside on execution wins or sector rallies. Some see it as a high-conviction play on AI in biotech.

**Bear Case (The "Clinical/Regulatory Risks, Cash Burn/Dilution Risks, Competition from Bigger Players, and 'Will It Ever Deliver Approved Drugs?' Crew")**  
Bears hammer on questions around converting early data to approved therapies, persistent negative cash flows requiring potential dilutive raises, entrenched competitors, customer/partner concentration risks, and historical precedent of AI/biotech plays struggling with timelines and profitability. Short buildup reflects skepticism that the vision justifies the price amid macro and execution hurdles.

**My First-Principles Take**: Biotech/AI drug discovery value accrues to concepts with proven scalability, cost-competitive development economics, sticky partnerships, and clear routes to positive margins—economics reward operational discipline and capital efficiency over pure tech bets in a regulation-, competition-, clinical validation-, and adoption-sensitive field. RXRX has genuine tailwinds from AI platform differentiation and momentum, but durable profits only come if cash burn moderates without endless dilution, differentiation sticks vs. bigger players, and pipeline converts to real value. The AI-biotech bet is directionally exposed to healthcare innovation trends, yet it's an execution-, capital-, and cycle-sensitive play prone to volatility and multiple compression. At these short levels, volatility grenade—positive catalysts roast shorts; weakness feeds the fire. High-risk, high-reward for the bold.

### 3. Groupon (GRPN) – Deal-Site Comeback King or Retail Relic in a Promo Fatigue Recession?
GRPN carries notable short interest (~32-51% of float in recent trackers, with days-to-cover around 9-14+), reflecting skepticism on a deals platform amid retail shifts.[[1]](https://www.findmymoat.com/short-interest)[[2]](https://thedesperatetrader.com/most-shorted-stocks)

**Bull Case (The "Local Deals Resilience, Cost Cuts, and Digital Advertising Pivot Crew")**  
Bulls highlight completed operational streamlining for breathing room, real estate/digital asset monetization generating cash, potential brand refresh via partnerships to drive user frequency, and early signs of stabilization as comps ease. Some see it as a leveraged play on consumer recovery in value-oriented local services and multiple expansion if margins rebound.

**Bear Case (The "Persistent User Declines, Competition from Giants, Margin Pressures, and 'Will Engagement Ever Inflect?' Crew")**  
Bears hammer on repeated user/engagement drops, higher marketing/labor costs crushing margins, intense competition from bigger platforms, and questions on whether turnaround execution delivers sustainable growth amid macro headwinds. Short buildup reflects conviction that the story is overhyped relative to near-term risks.

**My First-Principles Take**: Local commerce platforms accrue value to brands with sticky user loyalty, efficient unit economics (acquisition/retention costs controlled), scalable marketplace models, and paths to positive free cash flow—economics reward operational discipline and relevance over raw expansion bets in a competition-, consumer spending-, and macro-sensitive field. GRPN has genuine tailwinds from cost discipline and potential marketing catalysts, but durable profits only come if user trends stabilize without endless promotions, merchant health holds, and margins expand without massive reinvestment. The deals bet is directionally exposed to value-seeking trends, yet it's an execution-, capital-, and macro-sensitive play prone to volatility and multiple compression. At these short levels (and days-to-cover), volatility grenade—positive catalysts roast shorts; weakness feeds the fire. High-risk, high-reward for the bold.

There you have it—three fresh brawls proving disagreement is the market's favorite drug. Do your own damn homework, size like an adult, and remember: the tape stays irrational longer than your margin account can breathe. Sources pulled from latest short interest data (e.g., FINRA via trackers like FindMyMoat, MarketBeat, AltIndex, Benzinga, TheTrading.Tools, ShortInterestTracker, and related screens), company filings/press releases, analyst notes, and options flow as of late September/early October 2026. Trade responsibly, you magnificent animals.
